Second-Line Home Therapy Outcomes in Patients With Status Epilepticus - Neurology Advisor

-

Allocation of a second-line home medication for patients with refractory convulsive status epilepticus did not have an effect on clinical seizure cessation, according to study results published in Neurology.

Up to half of patients with status epilepticus are benzodiazepine non-responders. As this is the standard first-line therapy, there remains an urgent need for determining which second-line therapies effectively reduce seizures. The objective of the current study was to determine whether a second-line anticonvulsant medication that is part of a patient's home regimen can influence outcomes for patients with benzodiazepine- refractory convulsive status epilepticus.

Researchers conducted a tertiary analysis of the Established Status Epilepticus Treatment Trial which was a double-blind comparative study. Patients (N=232) with status epilepticus who presented at 57 emergency departments in the United States with ongoing convulsive seizures were randomized to receive 60 mg/kg levetiracetam, 20 mg/kg fosphenytoin, or 40 mg/kg valproate. Use of the randomized medication at home was associated with the primary outcome of clinical seizure cessation and improved consciousness at 60 minutes.

Continue Reading

A total of 89 participants used their medication at home and 143 used nonhome medications. The home and nonhome medication cohorts were aged mean 33 (standard deviation [SD], 26) and 30 (SD, 24) years, 56% and 60% were men or boys, and 47% and 46% were Black, respectively.

Patients reported taking levetiracetam only (74%), levetiracetam and valproate (7%), valproate only (7%), levetiracetam and phenytoin (6%), phenytoin only (5%), and phenytoin and valproate (1%).

Seizure cessation within 60 minutes was reported by 44% who took their allocated home medication and 53% who took a nonhome medication (odds ratio [OR], 0.69; 95% CI, 0.40-1.17; P =.17). Adjudicated seizure cessation was achieved by 42% of the home medication and 57% of the nonhome medication cohorts (OR, 0.53; 95% CI, 0.31-0.90; P =.02).

No significant differences were observed for adverse effects, except more in the home group had acute seizure recurrence 60 minutes to 12 hours after drug infusion (20% vs 10%; P =.05).

This study was limited by the fact that this secondary analysis was not prespecified in the original trial design.

These data indicated that there were no clear differences in these second-line therapies for refractory convulsive status epilepticus.

"However, the significant benefit seen on the secondary adjudicated outcome and the direction of the point estimates on the primary outcome suggests that it may be preferable to treat those who present in status epilepticus with a nonhome anticonvulsant," the researchers wrote. "Selecting a nonhome anticonvulsant medication could inform a novel and practical approach to a key therapeutic decision, often under the clinician's immediate control at the bedside, with potential to improve outcomes for patients with status epilepticus."

Reference

Wabl R, Terman SW, Kwok M, et al. Efficacy of Home Anticonvulsant Administration for Second-Line Status Epilepticus Treatment. Neurology. Published online June 29, 2021. doi:10.1212/WNL.0000000000012414

Topics:

Epilepsy Seizure Disorders

Comments

Post a Comment

Popular posts from this blog

Manual on meat inspection for developing countries

-
Image
sinusitis treatment :: Article Creator My 'sinus Infection' Turned Out To Be A One In A Million Nasal Cancer At Just 28 - And Doctors Had To Cut My Eye Out To Save Me By Emily Joshu Health Reporter For Dailymail.Com Published: 06:33 EDT, 20 April 2024Updated: 06:35 EDT, 20 April 2024 A 28 year-old California woman has described the shock of being diagnosed with a deadly sinus cancer that affects fewer than one in a million people - and led to the removal of her right eye. The 'golf ball-sized tumor', which had spread throughout her face, was first mistaken for a sinus infection by the woman's doctors.  Annika, who posts about her condition on TikTok, woke up one morning in 2023 and noticed that the inner corner of her right eye was sore.  While she at first thought nothing of it, by the time the evening rolled around, 'my face started to really, really hurt on the right side,' she said in a video.  The next day, her
Read more

Rash behind ear: Causes, other symptoms, and treatment - Medical News Today

-
Image
A rash behind the ear may occur due to a variety of different medical conditions. Certain viral infections and autoimmune diseases may cause a rash behind the ear in both children and adults. While some causes, such as contact dermatitis, are not concerning, other causes, including rubella, may be more serious. In this article, we look at some of the causes of a rash behind the ear, as well as the other symptoms that they may produce and how to treat them. Contact dermatitis is an allergic reaction to a particular substance. If an allergy-inducing substance comes into contact with the skin behind the ear, a rash can form. Allergens that may cause contact dermatitis behind the ears include: shampoos soaps other hair care products For example, hair dye products contain an ingredient called paraphenylenediamine (PPD), which is a common contact allergen. Symptoms Contact dermatitis causes itchiness, dryness, and flaking of the skin that came into contact with the allergen. Diagnosis A doc
Read more

Having This One Particular Blood Type Can Help Protect You From Severe Malaria - ScienceAlert

-
Image
Nearly  half the world's population is at risk of malaria, one of the most deadly diseases known to humankind. Each year it claims  over 400,000 lives, most of whom are children younger than age five. While it's possible to vaccinate against malaria, virtually all of these cases are in the African region, where protection is often nothing more than a roll of the dice. Now, a recent  analysis  of 23 papers suggests those with blood type O have the genetic odds stacked in their favour. In sub-Saharan Africa, where severe malaria - caused by the  Plasmodium falciparum  parasite  - is endemic, there are far more individuals with blood type O than anywhere in Europe or the US. In Nigeria alone, where 97 percent of the country is at risk of malaria, more than half the population belongs to this blood group. In Ethiopia and many others, the numbers are similar. Rather than a coincidence, co-author and epidemiologist Abraham Degarege Mengist from Robert Stempel College of Publi
Read more